Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shi-Ming Tu

Showing results (111-120 of 131) with videos related to

Pageof 14
Sort By:
Cells|May 13, 2025
Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of CancersJamaal C Jackson, Darren Sanchez, Aron Y Joon, et al.
Molecular Cancer Therapeutics|March 30, 2020
Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture <i>In Vitro</i> and Reduces Bone Osteolysis <i>In Vivo</i>Tianhong Pan, Mariane Martinez, Kelsea M Hubka, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
European Urology|December 6, 2020
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional TherapiesWeranja Ranasinghe, Daniel D Shapiro, Hyunsoo Hwang, et al.
Cancer|September 17, 2020
Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classificationsEric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Cancers|December 17, 2020
Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell TumorEric C Umbreit, Bilal A Siddiqui, Michael J Hwang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Pageof 14

Showing results (111-120 of 131) with videos related to

Sort By:
Pageof 14
Cells|May 13, 2025
Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of CancersJamaal C Jackson, Darren Sanchez, Aron Y Joon, et al.
Molecular Cancer Therapeutics|March 30, 2020
Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture <i>In Vitro</i> and Reduces Bone Osteolysis <i>In Vivo</i>Tianhong Pan, Mariane Martinez, Kelsea M Hubka, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancerNicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, et al.
European Urology|December 6, 2020
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional TherapiesWeranja Ranasinghe, Daniel D Shapiro, Hyunsoo Hwang, et al.
Cancer|September 17, 2020
Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classificationsEric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, et al.
The Lancet. Oncology|September 14, 2019
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trialPaul G Corn, Elisabeth I Heath, Amado Zurita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Cancers|December 17, 2020
Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell TumorEric C Umbreit, Bilal A Siddiqui, Michael J Hwang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Pageof 14